logo-loader

Venn Life Sciences gets under the skin of American market

Published: 02:50 02 Apr 2015 EDT

testubes_551ce70209c18

Venn Life Sciences (LON:VENN), the contract research firm that has also developed a highly advanced living skin, has revealed significant progress in the US.

Not only has it made its first American sales, the company has increased its product line there.

Earlier it said its unit InnoVenn shipped to a leading cosmetics, personal care and chemical testing group in Michigan that is carrying out tests to measure skin metabolism in different environments.

At the same it confirmed it has introduced a new 12 well-plates version of the research-grade synthetic human skin called Labskin to the States.

This particular product is ideally suited smaller clinical studies, where its existing six-plate creation is used for large-scale samples and repeated sampling.

Chief executive Tony Richardson said: "This expansion of InnoVenn's product line illustrates that this part of the business is growing independently of the contract research outsourcing business, which is our strategic plan, allowing InnoVenn to be well positioned to deliver on the full potential of its technology portfolio.

“Labskin continues to break barriers in terms of its capacity to replicate human skin and colonise microflora and we look forward to bringing Labskin to a global audience."

Poolbeg Pharma chair discusses shift to executive role; hVIVO share sale

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss his new hands-on role at the company. Stepping up as the executive chairman at Poolbeg Pharma, Friel expressed his intention to replicate the success he achieved with hVIVO, another...

on 02/15/2024